Skip to main content
SpringerLink
Log in

Primärprävention des Diabetes mellitus Typ 2

Metformingabe oder Östrogensubstitution

Primary prevention of type 2 diabetes mellitus

Administration of metformin or estrogen substitution

  • Menopause und Frauengesundheit
  • Published:
Gynäkologische Endokrinologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Schwabe U, Paffrath D (Hrsg) (2015) Arzneiverordnungs-Report 2015. Springer, Berlin

  2. Schäfer-Graf U et al (2015) Metformin vor und in der Schwangerschaft bei PCOS und Kinderwunsch. Frauenarzt 2015(12) 1074–1082

    Google Scholar 

  3. Wenderlein JM (2014) Hormonsubstitution ab der Menopause reduziert Gesamt-Mortalität. Gyne 10:14–21

    Google Scholar 

  4. Hung SC et al (2015) Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective observational, cohort study. Lancet Diabetes Endocrinol 3:605–614

    Article  CAS  PubMed  Google Scholar 

  5. Stram DO et al (2011) Age-specific effects of hormone therapy use on overall mortality and ischemic heart disease mortality among women in the California Teachers Study. Menopause 18(3):253–261

    Article  PubMed  PubMed Central  Google Scholar 

  6. Wenderlein JM (2014) Hormonelle Diabetes-Prävention als gynäkologische Herausforderung. Gyne 11–12:16–21

    Google Scholar 

  7. Wenderlein JM (2015) Östrogene verbessern Lipid-Profil. Gyne 1:35–40

    Google Scholar 

  8. Check Hayden E (2015) Anti-aging pill pushed as bona fide drug. Nature 522:265–266. doi:10.1038/522265a. http://www.nature.com/news/anti-ageing-pill-pushed-as-bona-fide-drug-1.17769

    Article  CAS  PubMed  Google Scholar 

  9. Schatz H (2014) Metformin – wo ist die Evidenz? Rury Holman aus Oxford: „Die Evidenz ist unklar“. DGE-Blogbeitrag vom 19. September 2014

  10. Moore EM et al (2013) Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care 36:3850. http://care.diabetesjournals.org/content/early/2013/08/29/dc13-0229

    Article  CAS  PubMed Central  Google Scholar 

  11. Bannister CA et al (2014) Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non‐diabetic controls. Diabetes Obes Metab 16(11):1165–1173

    Article  CAS  PubMed  Google Scholar 

  12. Preiss D et al (2013) Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes Endocrinol 2(2):116–124

    Article  PubMed  Google Scholar 

  13. Libby G et al (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32(9):1620–1625. doi:10.2337/dc08-2175. PMID 19564453. PMC 2732153

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:837–865

    Article  Google Scholar 

  15. Mikkola TS et al (2015) Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy. J Clin Endocrinol Metab. doi:10.1210/jc.2015-1864

    PubMed  Google Scholar 

  16. de Villiers TJ et al (2013) Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 16(3):316–337

    Article  PubMed  Google Scholar 

  17. Salpeter SR et al (2006) Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 21(4):363–366

    Article  PubMed  PubMed Central  Google Scholar 

  18. Rossouw JE et al (2007) Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297(13):1465–1477

    Article  CAS  PubMed  Google Scholar 

  19. Schierbeck LL et al (2012) Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 345:e6409

    Article  PubMed  Google Scholar 

  20. Tanaka R et al (2012) Protective effect of 17β-estradiol on ischemic acute kidney injury through the renal sympathetic nervous system. Eur J Pharmacol 683:270–275

    Article  CAS  PubMed  Google Scholar 

  21. Jia G et al (2014) Estrogen and mitochondria function in cardiorenal metabolic syndrome. Prog Mol Biol Transl Sci 127:229–249. doi:10.1016/B978-0-12-394625-600009-X

    Article  PubMed  PubMed Central  Google Scholar 

  22. National Health and Nutrition Examination Survey (NHANES). http://www.cdc.gov/nchs/nhanes.htm. Zugegriffen: 11. Feb. 2016

  23. de Groot-Kamphuis S (2013) Vitamin B12 deficiency and the lack of its consequences in type 2 diabetes patients using metformin. Neth J Med 71(7):386–390

    PubMed  Google Scholar 

  24. Wang J et al (2012) Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. Cell Stem Cell 11(1):23–35. doi:10.1016/j.stem.2012.03.016

    Article  CAS  PubMed  Google Scholar 

  25. Kickstein E et al (2010) Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci U S A 107(50):21830–21835. doi:10.1073/pnas.0912793107

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Rocca WA (2007) Increased risk of cognitive impairment on dementia in women who underwent oophorectomy before menopause. Neurology 9:1072–1089

    Google Scholar 

  27. Diabetes Prevention Program Research Group (2009) 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374(9702):1677–1686

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universität Ulm, Ulm, Deutschland

    J. M. Wenderlein

Authors
  1. J. M. Wenderlein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. M. Wenderlein.

Ethics declarations

Interessenkonflikt

J.M. Wenderlein gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine vom Autor durchgeführte Studien an Menschen oder Tieren.

Additional information

Redaktion

L. Kiesel, Münster

A.O. Mueck, Tübingen

P. Stute, Bern

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wenderlein, J.M. Primärprävention des Diabetes mellitus Typ 2. Gynäkologische Endokrinologie 14, 142–148 (2016). https://doi.org/10.1007/s10304-016-0056-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10304-016-0056-4

Search

Navigation